| Year |
Citation |
Score |
| 2023 |
Qi A, Kling HE, Billard N, Rodriguez AL, Peng L, Dickerson JW, Engers JL, Bender AM, Moehle MS, Lindsley CW, Rook JM, Niswender CM. . Molecular Pharmacology. PMID 37595966 DOI: 10.1124/molpharm.122.000643 |
0.305 |
|
| 2021 |
Moehle MS, Bender AM, Dickerson JW, Foster DJ, Qi A, Cho HP, Donsante Y, Peng W, Bryant Z, Stillwell KJ, Bridges TM, Chang S, Watson KJ, O'Neill JC, Engers JL, ... ... Rook JM, et al. Discovery of the First Selective M Muscarinic Acetylcholine Receptor Antagonists with Antiparkinsonian and Antidystonic Efficacy. Acs Pharmacology & Translational Science. 4: 1306-1321. PMID 34423268 DOI: 10.1021/acsptsci.0c00162 |
0.33 |
|
| 2021 |
Spock M, Carter TR, Bollinger KA, Han C, Baker LA, Rodriguez AL, Peng L, Dickerson JW, Qi A, Rook JM, O'Neill JC, Watson KJ, Chang S, Bridges TM, Engers JL, et al. Discovery of VU6028418: A Highly Selective and Orally Bioavailable M Muscarinic Acetylcholine Receptor Antagonist. Acs Medicinal Chemistry Letters. 12: 1342-1349. PMID 34413964 DOI: 10.1021/acsmedchemlett.1c00363 |
0.308 |
|
| 2019 |
Moran SP, Xiang Z, Doyle CA, Maksymetz J, Lv X, Faltin S, Fisher NM, Niswender CM, Rook JM, Lindsley CW, Conn PJ. Biased M receptor-positive allosteric modulators reveal role of phospholipase D in M-dependent rodent cortical plasticity. Science Signaling. 12. PMID 31796631 DOI: 10.1126/Scisignal.Aax2057 |
0.425 |
|
| 2019 |
Rook JM, Newhouse PA, Lindsley CW, Conn PJ. OPTIMIZATION OF NOVEL M1 PAMS FOR CLINICAL DEVELOPMENT WITH ENHANCED EFFICACY WHILE AVOIDING ADVERSE EFFECT LIABILITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE Alzheimer's & Dementia. 15: P1592-P1593. DOI: 10.1016/J.Jalz.2019.09.046 |
0.312 |
|
| 2018 |
Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW. VU6007477, a Novel M PAM Based on a Pyrrolo[2,3-]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. Acs Medicinal Chemistry Letters. 9: 917-922. PMID 30258541 DOI: 10.1021/Acsmedchemlett.8B00261 |
0.362 |
|
| 2018 |
Engers JL, Bender AM, Kalbfleisch JJ, Cho HP, Ligenfelter KS, Luscombe VB, Han C, Melancon B, Blobaum AL, Dickerson JW, Rook JM, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW. Discovery of tricyclic triazolo- and imidazopyridine lactams as M1 positive allosteric modulators (PAMs). Acs Chemical Neuroscience. PMID 30086237 DOI: 10.1021/Acschemneuro.8B00311 |
0.363 |
|
| 2018 |
Cieślik P, Woźniak M, Rook JM, Tantawy MN, Conn PJ, Acher F, Tokarski K, Kusek M, Pilc A, Wierońska JM. Mutual activation of glutamatergic mGlu and muscarinic M receptors reverses schizophrenia-related changes in rodents. Psychopharmacology. PMID 30054675 DOI: 10.1007/S00213-018-4980-Y |
0.408 |
|
| 2018 |
Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW. The discovery of VU0486846: steep SAR from a series of M PAMs based on a novel benzomorpholine core. Bioorganic & Medicinal Chemistry Letters. PMID 29754948 DOI: 10.1016/J.Bmcl.2018.05.009 |
0.347 |
|
| 2018 |
Rook JM, Bertron JL, Cho HP, Garcia-Barrantes PM, Moran SP, Maksymetz JT, Nance KD, Dickerson JW, Remke DH, Chang S, Harp J, Blobaum AL, Niswender CM, Jones CK, Stauffer SR, et al. A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. Acs Chemical Neuroscience. PMID 29701957 DOI: 10.1021/Acschemneuro.8B00131 |
0.443 |
|
| 2018 |
Moran SP, Cho HP, Maksymetz J, Remke DH, Hanson RM, Niswender CM, Lindsley CW, Rook JM, Conn PJ. PF-06827443 displays robust allosteric agonist and positive allosteric modulator activity in high receptor reserve and native systems. Acs Chemical Neuroscience. PMID 29683646 DOI: 10.1021/Acschemneuro.8B00106 |
0.463 |
|
| 2018 |
Turner BD, Rook JM, Lindsley CW, Conn PJ, Grueter BA. mGlu and mGlu modulate distinct excitatory inputs to the nucleus accumbens shell. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29654259 DOI: 10.1038/S41386-018-0049-1 |
0.346 |
|
| 2018 |
Moran SP, Dickerson JW, Cho HP, Xiang Z, Maksymetz J, Remke DH, Lv X, Doyle CA, Rajan DH, Niswender CM, Engers DW, Lindsley CW, Rook JM, Conn PJ. M-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29581537 DOI: 10.1038/S41386-018-0033-9 |
0.401 |
|
| 2017 |
Moehle MS, Pancani T, Byun N, Yohn SE, Wilson GH, Dickerson JW, Remke DH, Xiang Z, Niswender CM, Wess J, Jones CK, Lindsley CW, Rook JM, Conn PJ. Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron. 96: 1358-1372.e4. PMID 29268098 DOI: 10.1016/J.Neuron.2017.12.008 |
0.358 |
|
| 2017 |
Ghoshal A, Moran SP, Dickerson JW, Joffe ME, Grueter BA, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Role of mGlu5 receptors and inhibitory neurotransmission in M1 dependent muscarinic LTD in the prefrontal cortex: implications in schizophrenia. Acs Chemical Neuroscience. PMID 28679049 DOI: 10.1021/Acschemneuro.7B00167 |
0.469 |
|
| 2017 |
Walker AG, Sheffler DJ, Lewis AS, Dickerson JW, Foster DJ, Senter RK, Moehle MS, Lv X, Stansley BJ, Xiang Z, Rook JM, Emmitte KA, Lindsley CW, Conn PJ. Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP, Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28664928 DOI: 10.1038/Npp.2017.136 |
0.445 |
|
| 2017 |
Felts AS, Rodriguez AL, Blobaum AL, Morrison RD, Bates BS, Thompson Gray A, Rook JM, Tantawy MN, Byers FW, Chang S, Venable DF, Luscombe VB, Tamagnan GD, Niswender CM, Daniels JS, et al. Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation. Journal of Medicinal Chemistry. PMID 28530802 DOI: 10.1021/Acs.Jmedchem.7B00410 |
0.384 |
|
| 2017 |
Lv X, Dickerson JW, Rook JM, Lindsley CW, Conn PJ, Xiang Z. M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. Neuropharmacology. PMID 28336323 DOI: 10.1016/J.Neuropharm.2017.03.017 |
0.399 |
|
| 2016 |
Rook JM, Abe M, Cho HP, Nance KD, Luscombe VB, Adams JJ, Dickerson JW, Remke DH, Garcia-Barrantes PM, Engers DW, Engers JL, Chang S, Foster JJ, Blobaum AL, Niswender CM, et al. Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs. Acs Chemical Neuroscience. PMID 28001356 DOI: 10.1021/Acschemneuro.6B00429 |
0.429 |
|
| 2016 |
Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron. PMID 27618677 DOI: 10.1016/J.Neuron.2016.08.017 |
0.429 |
|
| 2016 |
Bertron JL, Ennis EA, Tarr CJ, Wright J, Dickerson JW, Locuson CW, Blobaum AL, Rook JM, Blakely RD, Lindsley CW. Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound. Bioorganic & Medicinal Chemistry Letters. PMID 27575469 DOI: 10.1016/J.Bmcl.2016.08.062 |
0.324 |
|
| 2016 |
Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT. An mGlu5 Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26741285 DOI: 10.1038/Npp.2016.2 |
0.381 |
|
| 2016 |
Rook JM, Lindsley CW, Conn PJ. O1-04-05: Selective Potentiation Of Muscarinic Acetylcholine Receptor Subtype 1 Demonstrates Efficacy And Safety In Preclinical Models Of Alzheimer's Disease Alzheimer's & Dementia. 12: P181-P182. DOI: 10.1016/J.Jalz.2016.06.314 |
0.315 |
|
| 2015 |
Pancani T, Foster DJ, Moehle MS, Bichell TJ, Bradley E, Bridges TM, Klar R, Poslusney M, Rook JM, Daniels JS, Niswender CM, Jones CK, Wood MR, Bowman AB, Lindsley CW, et al. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proceedings of the National Academy of Sciences of the United States of America. 112: 14078-83. PMID 26508634 DOI: 10.1073/Pnas.1512812112 |
0.385 |
|
| 2015 |
Malosh C, Turlington M, Bridges TM, Rook JM, Noetzel MJ, Vinson PN, Steckler T, Lavreysen H, Mackie C, Bartolomé-Nebreda JM, Conde-Ceide S, Martínez-Viturro CM, Piedrafita M, Sánchez-Casado MR, Macdonald GJ, et al. Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorganic & Medicinal Chemistry Letters. PMID 26475522 DOI: 10.1016/J.Bmcl.2015.10.009 |
0.405 |
|
| 2015 |
Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW. Development of novel, CNS penetrant positive allosteric modulators for the metabotropic glutamate receptor subtype 1 (mGlu1), based on an N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide scaffold, that potentiate both wild type and mutant mGlu1 receptors found in schizophrenics. Journal of Medicinal Chemistry. PMID 26426481 DOI: 10.1021/Acs.Jmedchem.5B00727 |
0.423 |
|
| 2015 |
Gould RW, Amato RJ, Bubser M, Joffe ME, Nedelcovych MT, Thompson AD, Nickols HH, Yuh JP, Zhan X, Felts AS, Rodriguez AL, Morrison RD, Byers FW, Rook JM, Daniels JS, et al. Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26315507 DOI: 10.1038/Npp.2015.265 |
0.384 |
|
| 2015 |
Conde-Ceide S, Martínez-Viturro CM, Alcázar J, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Rook JM, Bridges TM, Daniels JS, Megens A, Langlois X, Drinkenburg WH, Ahnaou A, Niswender CM, et al. Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. Acs Medicinal Chemistry Letters. 6: 716-20. PMID 26157544 DOI: 10.1021/Acsmedchemlett.5B00181 |
0.397 |
|
| 2015 |
Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, Lamsal A, Noetzel MJ, Poslusney MS, Wood MR, Melancon BJ, Stauffer SR, Xiang Z, Daniels JS, Niswender CM, et al. Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26108886 DOI: 10.1038/Npp.2015.189 |
0.405 |
|
| 2015 |
Rook JM, Xiang Z, Lv X, Ghoshal A, Dickerson JW, Bridges TM, Johnson KA, Foster DJ, Gregory KJ, Vinson PN, Thompson AD, Byun N, Collier RL, Bubser M, Nedelcovych MT, et al. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Neuron. 86: 1029-40. PMID 25937172 DOI: 10.1016/J.Neuron.2015.03.063 |
0.421 |
|
| 2015 |
Burket JA, Benson AD, Green TL, Rook JM, Lindsley CW, Conn PJ, Deutsch SI. Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 61: 10-7. PMID 25784602 DOI: 10.1016/J.Pnpbp.2015.03.003 |
0.355 |
|
| 2015 |
Walker AG, Wenthur CJ, Xiang Z, Rook JM, Emmitte KA, Niswender CM, Lindsley CW, Conn PJ. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Proceedings of the National Academy of Sciences of the United States of America. 112: 1196-201. PMID 25583490 DOI: 10.1073/Pnas.1416196112 |
0.372 |
|
| 2015 |
Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 755-65. PMID 25241804 DOI: 10.1038/Npp.2014.245 |
0.381 |
|
| 2014 |
Gregory KJ, Nguyen ED, Malosh C, Mendenhall JL, Zic JZ, Bates BS, Noetzel MJ, Squire EF, Turner EM, Rook JM, Emmitte KA, Stauffer SR, Lindsley CW, Meiler J, Conn PJ. Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. Acs Chemical Neuroscience. 5: 282-95. PMID 24528109 DOI: 10.1021/Cn400225X |
0.369 |
|
| 2014 |
Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatric Disease and Treatment. 10: 183-91. PMID 24511233 DOI: 10.2147/Ndt.S55104 |
0.423 |
|
| 2013 |
Turlington M, Noetzel MJ, Chun A, Zhou Y, Gogliotti RD, Nguyen ED, Gregory KJ, Vinson PN, Rook JM, Gogi KK, Xiang Z, Bridges TM, Daniels JS, Jones C, Niswender CM, et al. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Journal of Medicinal Chemistry. 56: 7976-96. PMID 24050755 DOI: 10.1021/Jm401028T |
0.428 |
|
| 2013 |
Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Xiang Z, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1703-14. PMID 23821185 DOI: 10.1124/Dmd.113.052084 |
0.467 |
|
| 2013 |
Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, et al. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biological Psychiatry. 73: 501-9. PMID 23140665 DOI: 10.1016/J.Biopsych.2012.09.012 |
0.44 |
|
| 2012 |
Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Molecular Pharmacology. 82: 860-75. PMID 22863693 DOI: 10.1124/Mol.112.080531 |
0.403 |
|
| 2012 |
Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Molecular Pharmacology. 81: 120-33. PMID 22021324 DOI: 10.1124/Mol.111.075184 |
0.442 |
|
| 2011 |
Sheffler DJ, Gregory KJ, Rook JM, Conn PJ. Allosteric modulation of metabotropic glutamate receptors. Advances in Pharmacology (San Diego, Calif.). 62: 37-77. PMID 21907906 DOI: 10.1016/B978-0-12-385952-5.00010-5 |
0.437 |
|
| 2010 |
Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Molecular Pharmacology. 78: 1105-23. PMID 20923853 DOI: 10.1124/Mol.110.067207 |
0.444 |
|
| 2009 |
Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. Journal of Medicinal Chemistry. 52: 4103-6. PMID 19537763 DOI: 10.1021/Jm900654C |
0.419 |
|
| 2009 |
Rook JM, Hasan W, McCarson KE. Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression. Biochemical Pharmacology. 77: 1747-55. PMID 19428329 DOI: 10.1016/J.Bcp.2009.03.003 |
0.631 |
|
| 2008 |
Rook JM, Hasan W, McCarson KE. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology. 109: 130-6. PMID 18580183 DOI: 10.1097/Aln.0B013E31817B5Ac3 |
0.609 |
|
| 2007 |
Rook JM, McCarson KE. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochemical Pharmacology. 74: 752-7. PMID 17632084 DOI: 10.1016/J.Bcp.2007.06.005 |
0.621 |
|
| Show low-probability matches. |